US FDA Strategy On Abuse-Deterrent Opioids Needs Rethinking, Panelists Say

Deterring intravenous abuse over other routes of abuse should be agency's priority, some advisory committee members say during discussion of abuse patterns and risks with Endo’s reformulated Opana ER.

The US FDA should rethink its approach to abuse-deterrent labeling for opioids, advisory committee members said at a meeting on the abuse risks with Endo Pharmaceuticals Inc.’s Opana ER (oxymorphone extended-release).

Given data showing a shift in abuse patterns following Endo’s reformulation of Opana ER that made the tablets harder to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers